BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has entered into a license agreement with the University of Cincinnati for exclusive worldwide rights to a portfolio of U.S. and international patents, which includes certain patents covering genetic markers for the Company’s lead drug candidate, GencaroTM (bucindolol hydrochloride), which is being developed for the treatment of chronic heart failure.
